For treatment of adult patients with active radiographic axial spondyloarthritis (rad-axSpA; also known as ankylosing spondylitis [AS] in the literature) who have responded inadequately to conventional therapy and adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Medicine details

Medicine name:
ixekizumab (Taltz)
Pharmaceutical company
Eli Lilly and Company Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Publication due date:
13 June 2022
SMC meeting date:
03 May 2022
Patient group submission deadline:
04 April 2022